|
|
||||||||
The Journal of Thoracic and Cardiovascular Surgery, Vol 96, 314-320, Copyright © 1988 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
M Sunamori, R Innami, J Amano, A Suzuki and CE Harrison
The effects of aprotinin on canine myocardium subjected to cardioplegia and
global ischemia for 4 hours and then reperfused for 1 hour were
investigated. Lysosomal and mitochondrial enzymes and cyclic nucleotides
(adenosine cyclic monophosphate and guanosine cyclic monophosphate) were
measured in coronary sinus blood. Aprotinin was given intravenously before
cardiopulmonary bypass at total doses of 10 X 10(3) kallikrein units per
kilogram (group A, six dogs) and 20 X 10(3) KU/kg (group B, six dogs). In
group A, three dogs survived but with poor cardiac function; all dogs in
group B survived and had better cardiac function. Lysosomal
(N-acetyl-beta-D-glucosaminidase) and mitochondrial (aspartate
aminotransferase) enzymes in coronary sinus blood at 60 minutes of
reperfusion were significantly (p less than 0.05) lower in group B than in
group A. In both groups, guanosine cyclic monophosphate was significantly
(p less than 0.01) lower during reperfusion than before cardiopulmonary
bypass; however, the values were significantly (p less than 0.05) higher in
group B than in group A. Serum adenosine cyclic monophosphate was lower
during reperfusion than before bypass in both groups, but it recovered
during reperfusion in group B. Myocardial adenosine triphosphate was well
preserved in both groups but creatine phosphate was decreased (p less than
0.01) in group A. These results suggest that aprotinin at a dose of 20 X
10(3) KU/kg may be effective in preserving myocardial viability and
function after prolonged cardioplegia.
ARTICLES
Role of protease inhibition in myocardial preservation in prolonged hypothermic cardioplegia followed by reperfusion. Effect of aprotinin in an experimental model
Department of Thoracic-Cardiovascular Surgery, Tokyo Medical and Dental University School of Medicine, Japan.
This article has been cited by other articles:
![]() |
T. A. Khan, C. Bianchi, P. Voisine, J. Feng, J. Baker, M. Hart, M. Takahashi, G. Stahl, and F. W. Sellke Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest J. Thorac. Cardiovasc. Surg., October 1, 2004; 128(4): 602 - 608. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rahman, B. Ustunda, O. Burma, I. H. Ozercan, A. Cekirdekci, and M. K. Bayar Does aprotinin reduce lung reperfusion damage after cardiopulmonary bypass? Eur. J. Cardiothorac. Surg., November 1, 2000; 18(5): 583 - 588. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. F. Roberts, G. P. Nishanian, J. N. Carey, S. H. Darbinian, J. D. Kim, Y. Sakamaki, J. Y. Chang, V. A. Starnes, and M. L. Barr Addition of aprotinin to organ preservation solutions decreases lung reperfusion injury Ann. Thorac. Surg., July 1, 1998; 66(1): 225 - 230. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Royston Systemic inflammatory responses to surgery with cardiopulmonary bypass Perfusion, May 1, 1996; 11(3): 177 - 189. [PDF] |
||||
![]() |
J. Gurevitch, J. Barak, E. Hochhauser, Y. Paz, and V. Yakirevich Aprotinin improves myocardial recovery after ischemia and reperfusion:Effects of the drug on isolated rat hearts J. Thorac. Cardiovasc. Surg., July 1, 1994; 108(1): 109 - 118. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |